The iodine atoms in iohexol provide attenuation of X-rays in direct proportion to the concentration of iohexol. Since concentration changes over time, iohexol provides time-dependent image contrast which may assist in visualizing body structures.

OMNIPAQUE is approved for use in:

Intrathecal (e.g., myelography, cisternography)

Intra-arterial (e.g., ventriculography, arteriography)

Intravenous (e.g., CT imaging, urography, DSA)

Oral/Rectal (e.g., GI tract imaging, abdominal CT)

Intraarticular (e.g., arthrography)

Body cavities (e.g., ERCP, hysterosalpingography, VCU)
→ Pediatric and adult dosing tables provided [Pages 4–15].

9 mg/mL and 12 mg/mL

Intrathecal (Adults): Headache (18%), back/neck pain (8%), nausea (6%)
IV/IA (Adults): Pain (3%), arrhythmias (2%), nausea (2%), blurred vision (2%)
Oral (Adults): Diarrhea (42%), nausea (15%), vomiting (11%)
Pediatric data is similar in type and frequency [Pages 21–25].

Especially for hysterosalpingography, OMNIPAQUE is contraindicated:

• During or suspected pregnancy

• Menstruation or imminent menstruation

• 6 months post-abortion

• 30 days post-conization/curettage

• Genital tract infections

• Known or suspected reproductive tract neoplasia

Severe hypersensitivity including fatal anaphylaxis

Acute kidney injury, especially with existing renal issues

Cardiovascular events, including shock and arrest

Thyroid dysfunction in pediatric patients ≤3 years

Severe cutaneous adverse reactions (SJS, TEN, DRESS)

Increased risk of seizures with intrathecal use [Pages 18–20]